Longboard Pharmaceuticals, INC

Longboard Pharmaceuticals has been acquired by H. Lundbeck A/S for $60 per share, completing the merger on December 2, 2024.

Casey Lynch, a director at Longboard Pharmaceuticals, disposed of multiple employee stock options as a result of the company's merger with a subsidiary of H. Lundbeck A/S.

A Longboard Pharmaceuticals director, Corinne Le Goff, disposed of multiple employee stock options as a result of the company's merger with a subsidiary of H. Lundbeck A/S.

Paul J. Sekhri, a director at Longboard Pharmaceuticals, cashed out his vested stock options for $60 per share following the company's merger with a subsidiary of H. Lundbeck A/S.

Phillip M. Schneider, a director at Longboard Pharmaceuticals, cashed out his vested stock options following the company's merger with a subsidiary of H. Lundbeck A/S.

A Form 4 filing reveals that a Longboard Pharmaceuticals director, Vincent Aurentz, had his unvested stock options accelerated and cashed out following the company's merger with a subsidiary of H. Lundbeck A/S.

An SEC Form 4 filing details the conversion of Longboard Pharmaceuticals executive Randall Kaye's stock options and restricted stock units into cash following the company's merger with a Lundbeck subsidiary.